Beta Bionics, Inc. 8-K Filing
On September 15, 2026, Beta Bionics, Inc. entered into an underwriting agreement for a public offering of 7,652,175 shares of common stock at $17.25 per share, and pre-funded warrants to purchase 1,043,484 shares of common stock at $17.2499 per share. The gross proceeds are expected to be approximately $150 million before expenses. The offering is expected to close on September 17, 2026. The company has granted the underwriters a 30-day option to purchase up to 1,304,348 additional shares. The net proceeds will be used for general corporate purposes, including commercialization of Mintβ’, manufacturing, R&D, and working capital. The underwriting agreement includes customary representations, warranties, and indemnification obligations. The offering is made under a Form S-3 registration statement. Beta Bionics also issued press releases on September 15, 2026, announcing the commencement and pricing of the offering.